Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Apr;71(4):660–665. doi: 10.1038/bjc.1995.131

Effect of tumour necrosis factor on the uptake of specific and control monoclonal antibodies in a human tumour xenograft model.

G Rowlinson-Busza 1, A Maraveyas 1, A A Epenetos 1
PMCID: PMC2033735  PMID: 7710925

Abstract

The investigations reported in this paper aim to exploit tumour necrosis factor (TNF)-induced vascular changes in an attempt to increase the tumour uptake of specific monoclonal antibody. The vascular permeability to monoclonal antibody of a human tumour xenograft increased 2.6-fold by 1 h post injection of 2.5 x 10(3) U of TNF, although this effect was lost by 3 h. The normal tissues also demonstrated increased vascular permeability to IgG, but to a lesser extent. Liver permeability increased 1.5-fold at 1 h but returned to the control value by 6 h. Lung permeability increased 1.4-fold at 1 h post injection and returned to normal by 3 h. Muscle values were not significantly increased compared with controls. The blood activity was cleared more quickly in the TNF-treated mice (t1/2 beta = 101 h, compared with 121 h in control mice). This was probably due to the increased vascular permeability in normal organs of treated mice. At 1 day and 3 days post injection, the tumour uptake of the specific, but not the control, antibody was significantly increased by 25% and 29% respectively. This resulted in an increase in the area under the tumour activity curve, and therefore tumour radiation dose, of 25% in treated compared with control mice. In addition, a consequence of the faster blood clearance of the isotope in the TNF-treated mice was a reduction in the area under the blood activity curve of 12%, thereby reducing systemic toxicity. The increase in vascular permeability to IgG following TNF injection resulted in both specific and control antibodies having improved access to the tumour antigens, and a transient increase in uptake was observed. Only in the case of the specific antibody was the increase maintained, since this antibody binds to the available antigenic sites, whereas the control antibody was cleared from the tumour without binding. No evidence of tumour necrosis was observed at the TNF doses given, nor was there any toxicity to the mice.

Full text

PDF
660

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abbruzzese J. L., Levin B., Ajani J. A., Faintuch J. S., Saks S., Patt Y. Z., Edwards C., Ende K., Gutterman J. U. Phase I trial of recombinant human gamma-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer. Cancer Res. 1989 Jul 15;49(14):4057–4061. [PubMed] [Google Scholar]
  2. Aicher K. P., Dupon J. W., White D. L., Aukerman S. L., Moseley M. E., Juster R., Rosenau W., Winkelhake J. L., Brasch R. C. Contrast-enhanced magnetic resonance imaging of tumor-bearing mice treated with human recombinant tumor necrosis factor alpha. Cancer Res. 1990 Nov 15;50(22):7376–7381. [PubMed] [Google Scholar]
  3. Arklie J., Taylor-Papadimitrious J., Bodmer W., Egan M., Millis R. Differentiation antigens expressed by epithelial cells in the lactating breast are also detectable in breast cancers. Int J Cancer. 1981 Jul 15;28(1):23–29. doi: 10.1002/ijc.2910280105. [DOI] [PubMed] [Google Scholar]
  4. BRUNSON J. G., GAMBLE C. N., THOMAS L. Morphologic changes in rabbits following the intravenous administration of meningococcal toxin. I. The effects produced in young and in mature animals by a single injection. Am J Pathol. 1955 May-Jun;31(3):489–499. [PMC free article] [PubMed] [Google Scholar]
  5. Bomber P., McCready R., Hammersley P. Propranolol hydrochloride enhancement of tumor perfusion and uptake of gallium-67 in a mouse sarcoma. J Nucl Med. 1986 Feb;27(2):243–245. [PubMed] [Google Scholar]
  6. Burchell J., Gendler S., Taylor-Papadimitriou J., Girling A., Lewis A., Millis R., Lamport D. Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res. 1987 Oct 15;47(20):5476–5482. [PubMed] [Google Scholar]
  7. Chan R. C., Babbs C. F., Vetter R. J., Lamar C. H. Abnormal response of tumor vasculature to vasoactive drugs. J Natl Cancer Inst. 1984 Jan;72(1):145–150. doi: 10.1093/jnci/72.1.145. [DOI] [PubMed] [Google Scholar]
  8. Coley W. B. II. Contribution to the Knowledge of Sarcoma. Ann Surg. 1891 Sep;14(3):199–220. doi: 10.1097/00000658-189112000-00015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Ettinghausen S. E., Puri R. K., Rosenberg S. A. Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice. J Natl Cancer Inst. 1988 Apr 6;80(3):177–188. doi: 10.1093/jnci/80.3.177. [DOI] [PubMed] [Google Scholar]
  10. Folli S., Pèlegrin A., Chalandon Y., Yao X., Buchegger F., Lienard D., Lejeune F., Mach J. P. Tumor-necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability. Int J Cancer. 1993 Mar 12;53(5):829–836. doi: 10.1002/ijc.2910530521. [DOI] [PubMed] [Google Scholar]
  11. Fraker P. J., Speck J. C., Jr Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res Commun. 1978 Feb 28;80(4):849–857. doi: 10.1016/0006-291x(78)91322-0. [DOI] [PubMed] [Google Scholar]
  12. Hoogenboom H. R., Raus J. C., Volckaert G. Targeting of tumor necrosis factor to tumor cells: secretion by myeloma cells of a genetically engineered antibody-tumor necrosis factor hybrid molecule. Biochim Biophys Acta. 1991 Jun 5;1096(4):345–354. doi: 10.1016/0925-4439(91)90071-g. [DOI] [PubMed] [Google Scholar]
  13. Horvath C. J., Ferro T. J., Jesmok G., Malik A. B. Recombinant tumor necrosis factor increases pulmonary vascular permeability independent of neutrophils. Proc Natl Acad Sci U S A. 1988 Dec;85(23):9219–9223. doi: 10.1073/pnas.85.23.9219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Jain R. K., Baxter L. T. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res. 1988 Dec 15;48(24 Pt 1):7022–7032. [PubMed] [Google Scholar]
  15. Jain R. K. Haemodynamic and transport barriers to the treatment of solid tumours. Int J Radiat Biol. 1991 Jul-Aug;60(1-2):85–100. doi: 10.1080/09553009114551621. [DOI] [PubMed] [Google Scholar]
  16. Kallinowski F., Schaefer C., Tyler G., Vaupel P. In vivo targets of recombinant human tumour necrosis factor-alpha: blood flow, oxygen consumption and growth of isotransplanted rat tumours. Br J Cancer. 1989 Oct;60(4):555–560. doi: 10.1038/bjc.1989.312. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Melton R. G., Rowland J. A., Pietersz G. A., Sherwood R. F., McKenzie I. F. Tumour necrosis factor increases tumour uptake of co-administered antibody-carboxypeptidase G2 conjugate. Eur J Cancer. 1993;29A(8):1177–1183. doi: 10.1016/s0959-8049(05)80311-9. [DOI] [PubMed] [Google Scholar]
  18. Neta R., Douches S., Oppenheim J. J. Interleukin 1 is a radioprotector. J Immunol. 1986 Apr 1;136(7):2483–2485. [PubMed] [Google Scholar]
  19. Neta R., Oppenheim J. J., Douches S. D. Interdependence of the radioprotective effects of human recombinant interleukin 1 alpha, tumor necrosis factor alpha, granulocyte colony-stimulating factor, and murine recombinant granulocyte-macrophage colony-stimulating factor. J Immunol. 1988 Jan 1;140(1):108–111. [PubMed] [Google Scholar]
  20. Neta R., Oppenheim J. J., Schreiber R. D., Chizzonite R., Ledney G. D., MacVittie T. J. Role of cytokines (interleukin 1, tumor necrosis factor, and transforming growth factor beta) in natural and lipopolysaccharide-enhanced radioresistance. J Exp Med. 1991 May 1;173(5):1177–1182. doi: 10.1084/jem.173.5.1177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. O'Connor S. W., Bale W. F. Accessibility of circulating immunoglobulin G to the extravascular compartment of solid rat tumors. Cancer Res. 1984 Sep;44(9):3719–3723. [PubMed] [Google Scholar]
  22. Old L. J. Tumour necrosis factor. Another chapter in the long history of endotoxin. Nature. 1987 Dec 17;330(6149):602–603. doi: 10.1038/330602a0. [DOI] [PubMed] [Google Scholar]
  23. Pavel D. G., Zimmer M., Patterson V. N. In vivo labeling of red blood cells with 99mTc: a new approach to blood pool visualization. J Nucl Med. 1977 Mar;18(3):305–308. [PubMed] [Google Scholar]
  24. Pimm M. V., Gribben S. J., Morris T. M. Influence of recombinant tumour necrosis factor alpha on blood flow and antibody localisation in human tumour xenografts in nude mice. J Cancer Res Clin Oncol. 1991;117(6):543–548. doi: 10.1007/BF01613286. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Robertson P. A., Ross H. J., Figlin R. A. Tumor necrosis factor induces hemorrhagic necrosis of a sarcoma. Ann Intern Med. 1989 Oct 15;111(8):682–684. doi: 10.7326/0003-4819-111-8-682. [DOI] [PubMed] [Google Scholar]
  26. Rosenstein M., Ettinghausen S. E., Rosenberg S. A. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol. 1986 Sep 1;137(5):1735–1742. [PubMed] [Google Scholar]
  27. Rowlinson-Busza G., Bamias A., Krausz T., Epenetos A. A. Uptake and distribution of specific and control monoclonal antibodies in subcutaneous xenografts following intratumor injection. Cancer Res. 1991 Jun 15;51(12):3251–3256. [PubMed] [Google Scholar]
  28. Royall J. A., Berkow R. L., Beckman J. S., Cunningham M. K., Matalon S., Freeman B. A. Tumor necrosis factor and interleukin 1 alpha increase vascular endothelial permeability. Am J Physiol. 1989 Dec;257(6 Pt 1):L399–L410. doi: 10.1152/ajplung.1989.257.6.L399. [DOI] [PubMed] [Google Scholar]
  29. Russell S. M., Krauer K. G., McKenzie I. F., Pietersz G. A. Effect of tumor necrosis factor on the antitumor efficacy and toxicity of aminopterin-monoclonal antibody conjugates: parameters for optimization of therapy. Cancer Res. 1990 Sep 15;50(18):6028–6033. [PubMed] [Google Scholar]
  30. SMITH W. W., ALDERMAN I. M., GILLESPIE R. E. Increased survival in irradiated animals treated with bacterial endotoxins. Am J Physiol. 1957 Oct;191(1):124–130. doi: 10.1152/ajplegacy.1957.191.1.124. [DOI] [PubMed] [Google Scholar]
  31. Sands H., Jones P. L., Shah S. A., Palme D., Vessella R. L., Gallagher B. M. Correlation of vascular permeability and blood flow with monoclonal antibody uptake by human Clouser and renal cell xenografts. Cancer Res. 1988 Jan 1;48(1):188–193. [PubMed] [Google Scholar]
  32. Sands H., Shah S. A., Gallagher B. M. Vascular volume and permeability of human and murine tumors grown in athymic mice. Cancer Lett. 1985 May;27(1):15–21. doi: 10.1016/0304-3835(85)90004-7. [DOI] [PubMed] [Google Scholar]
  33. Sato N., Goto T., Haranaka K., Satomi N., Nariuchi H., Mano-Hirano Y., Sawasaki Y. Actions of tumor necrosis factor on cultured vascular endothelial cells: morphologic modulation, growth inhibition, and cytotoxicity. J Natl Cancer Inst. 1986 Jun;76(6):1113–1121. [PubMed] [Google Scholar]
  34. Savage P., So A., Spooner R. A., Epenetos A. A. A recombinant single chain antibody interleukin-2 fusion protein. Br J Cancer. 1993 Feb;67(2):304–310. doi: 10.1038/bjc.1993.57. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Shirai T., Yamaguchi H., Ito H., Todd C. W., Wallace R. B. Cloning and expression in Escherichia coli of the gene for human tumour necrosis factor. 1985 Feb 28-Mar 6Nature. 313(6005):803–806. doi: 10.1038/313803a0. [DOI] [PubMed] [Google Scholar]
  36. Slørdal L., Muench M. O., Warren D. J., Moore M. A. Radioprotection by murine and human tumor-necrosis factor: dose-dependent effects on hematopoiesis in the mouse. Eur J Haematol. 1989 Nov;43(5):428–434. doi: 10.1111/j.1600-0609.1989.tb00331.x. [DOI] [PubMed] [Google Scholar]
  37. Smyth M. J., Pietersz G. A., McKenzie I. F. Use of vasoactive agents to increase tumor perfusion and the antitumor efficacy of drug-monoclonal antibody conjugates. J Natl Cancer Inst. 1987 Dec;79(6):1367–1373. [PubMed] [Google Scholar]
  38. Song C. W., Levitt S. H. Effect of x irradiation on vascularity of normal tissues and experimental tumor. Radiology. 1970 Feb;94(2):445–447. doi: 10.1148/94.2.445. [DOI] [PubMed] [Google Scholar]
  39. Spurr N. K., Durbin H., Sheer D., Parkar M., Bobrow L., Bodmer W. F. Characterization and chromosomal assignment of a human cell surface antigen defined by the monoclonal antibody AUAI. Int J Cancer. 1986 Nov 15;38(5):631–636. doi: 10.1002/ijc.2910380503. [DOI] [PubMed] [Google Scholar]
  40. Tartaglia L. A., Weber R. F., Figari I. S., Reynolds C., Palladino M. A., Jr, Goeddel D. V. The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):9292–9296. doi: 10.1073/pnas.88.20.9292. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Taylor-Papadimitriou J., Peterson J. A., Arklie J., Burchell J., Ceriani R. L., Bodmer W. F. Monoclonal antibodies to epithelium-specific components of the human milk fat globule membrane: production and reaction with cells in culture. Int J Cancer. 1981 Jul 15;28(1):17–21. doi: 10.1002/ijc.2910280104. [DOI] [PubMed] [Google Scholar]
  42. Tracey K. J., Beutler B., Lowry S. F., Merryweather J., Wolpe S., Milsark I. W., Hariri R. J., Fahey T. J., 3rd, Zentella A., Albert J. D. Shock and tissue injury induced by recombinant human cachectin. Science. 1986 Oct 24;234(4775):470–474. doi: 10.1126/science.3764421. [DOI] [PubMed] [Google Scholar]
  43. Van de Wiel P. A., Bloksma N., Kuper C. F., Hofhuis F. M., Willers J. M. Macroscopic and microscopic early effects of tumour necrosis factor on murine Meth A sarcoma, and relation to curative activity. J Pathol. 1989 Jan;157(1):65–73. doi: 10.1002/path.1711570109. [DOI] [PubMed] [Google Scholar]
  44. Wong G. H., Goeddel D. V. Induction of manganous superoxide dismutase by tumor necrosis factor: possible protective mechanism. Science. 1988 Nov 11;242(4880):941–944. doi: 10.1126/science.3263703. [DOI] [PubMed] [Google Scholar]
  45. van de Weil P. A., Bouma G. J., van der Pijl A., Weitenberg E. S., Lam A. W., Bloksma N. Effect of tumour necrosis factor and lipid A on functional and structural vascular volume in solid murine tumours. Br J Cancer. 1990 Nov;62(5):718–723. doi: 10.1038/bjc.1990.366. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES